Steven Leonard Chapman Sells 4,400 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,400 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00. Following the sale, the chief executive officer directly owned 140,416 shares in the company, valued at $33,428,837.12. The trade was a 3.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88.
• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $449,067.20.
• On Tuesday, October 21st, Steven Leonard Chapman sold 1,603 shares of Natera stock. The shares were sold at an average price of $187.95, for a total value of $301,283.85.
• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The stock was sold at an average price of $160.00, for a total value of $2,253,280.00.
• On Tuesday, September 30th, Steven Leonard Chapman sold 9,109 shares of Natera stock. The stock was sold at an average price of $162.05, for a total value of $1,476,113.45.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $242.06 on Friday. The business has a fifty day moving average price of $197.92 and a 200-day moving average price of $173.04. The company has a market capitalization of $33.41 billion, a PE ratio of -105.70 and a beta of 1.63. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $243.73.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the previous year, the firm earned ($0.26) EPS. The business’s revenue for the quarter was up 34.7% on a year-over-year basis. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of Natera from $240.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, November 25th. UBS Group lifted their target price on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Stephens upped their price target on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Barclays increased their price objective on Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Morgan Stanley boosted their target price on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday. Fifteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $223.53.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. grew its position in Natera by 9.4% during the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after buying an additional 1,003,129 shares during the period. Price T Rowe Associates Inc. MD grew its position in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after buying an additional 3,795,315 shares during the period. State Street Corp increased its holdings in Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after acquiring an additional 727,366 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.